
NEXT GENERATION SEQUENCING IDENTIFIED A NOVEL
MULTI EXON DELETION OF THE NF1 GENE IN A CHINESE
PEDIGREE WITH NEUROFIBROMATOSIS TYPE 1 Yang J, An J-X, Liu X-L, Wang Z-Q, Xie G-M, Yang X-L, Xu S-J, Feng F, Ni Y
-- Jie Yang and Jinxia An contributed equally to this study. *Corresponding Author: Dr. Yali Ni, Gansu Provincial Maternity and Child-Care Hospital, 143 Qilihe
North Street, LanZhou, Gansu Province, 730050, People’s Republic of China. Tel.: +86-0931-2231241.
E-mail: niyali@126.com page: 45
|
CASE REPORTS
Two individuals in a Chinese family were clinically
diagnosed with NF1, based on the consensus criteria of
the National Institutes of Health (NIH) [2], at the Gansu
Provincial Maternity and Child-Care Hospital, LanZhou,
Gansu Province, People’s Republic of China (PRC) (Figure
1). In our hospital, detailed physical examination,
laboratory investigations were done. The proband (II-1)
was a 31-year-old Chinese male with neurofibroma and
café-au-lait macules on his chest and back [Figure 2(A),
2(B)]. In the proband, café-au-lait macules are gradually
increasing in size as well as developing new café-au-lait
macules. Several tender masses were identified on the
chest and back of the proband. Physical examination of
these tender masses were consistent with neurofibroma. The proband’s mother (I-2) was 65 years old and
presented with multiple subcutaneous neurofibromas and
café-au-lait spots [Figure 2(C), 2(D) and 2(E)]. The proband’s
father (I-1) was normal. Physical growth and cognitive
ability was normal and no other abnormality was
identified in either the proband or his mother.
The Ethics Committee of the Gansu Provincial Maternity
and Child-Care Hospital approved the present study.
Next generation sequencing (NGS) and Sanger sequencing
was performed to identify the candidate gene and mutation
in the proband. The proband’s blood sample was collected
and genomic DNA was extracted.
Next Generation Sequencing. DNA samples obtained
from the proband (II-1) were sequenced using target
exome-based NGS. A sequence capture human array
(Roche NimbleGen Inc., Madison, WI, USA) was designed
to capture the targeted sequence, covering all 57 exons and
flanking sequences (including the 100 bp introns) of the
NF1 genes that are associated with NF1. On average, there
are 6,857,687 reads per sample, with 87.48% of mapping
to the targeted regions. The average sequencing depth of
the target area was 428.14-times with 99.86% coverage.
The procedure for preparation of libraries was consistent
with standard operating protocols published previously
[3]. According to the standard protocol, we simultaneously
sequenced 30 samples on Illumina HiSeq
2500 Analyzers (Illumina, San Diego, CA, USA) for each
pooling batch of 90 cycles (specially designed rare disease
screening). We applied Illumina Pipeline software (version
1.3.4) to generate the raw data that was later used for
bioinformatic analysis. We extracted the clean reads from
the raw reads by using already established filtering criteria.
We then selectively used at least 90 bp long clean reads for
aligning to the human reference genome (Build 37) of the
National Center for Biotechnology Information (NCBI)
(https:// www.ncbi.nlm.nih.gov/grc) database using Burrows
Wheeler aligner (BWA). The BWA is a multi-vision
software package (http://bio-bwa.sourceforge.net/index.
shtml) generating the output file in BAM format. After that,
we analyzed the target region coverage, sequencing depth,
SNP/InDel/CNV detection by using the bam data. Later,
SOAPsnp software (www.soap/genomics.org.cn), Sam
tools pileup software (www.htslib.org) and Bioinformatic
computational framework (this explains the pipeline made
by the software), were established for identifying single
nucleotide polymorphisms (SNPs), insertions/deletions
(InsDels) and copy number variations (CNVs). Filtering
criteria for a SNP or InDel has been set with at least 10
reads with >20.0% of total reads. The SNPs are filtered
out if it’s frequency is <0.05 in dbSNP (www.ncbi.nlm.
nih. gov/projects/SNP/), Hapmap (https://www.genome.
gov), 1000 Genomes Project (http://www.1000genomes.
org), the 200 healthy reference samples sequenced in this
study, it would consider as a disease-causing mutation.
Identification of a Novel Heterozygous Multi Exon
Deletion in the NF1 Gene. Next generation sequencing
identified a novel multi exon c.(4661+1_4662-1)_(5748
+1_5749-1)del; EX36_39DEL deletion on the NF1 gene
in the proband and in his mother. This multi-exon deletion
leads to the formation of a truncated neurofibromin
instead of the wild type neurofibromin. This mutation
has been validated in proband and his parents by q-PCR Quantitative Real-Time Polymerase Chain Reaction
(qPCR). We performed qPCR to validate the multi
exon deletion on the NF1 gene identified by NGS. The
qPCR was performed using an ABI PRISM® 7900HT realtime
PCR system (Life Technologies, Carlsbad, CA, USA)
and hot-start qPCR Master Mix. The primer sequences
and PCR conditions will be provided by the corresponding
author upon request. Data were analyzed using the
comparative threshold cycle (2–ΔΔCt) method.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|